BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30720692)

  • 1. Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
    Botejue M; Abbott D; Danella J; Fonshell C; Ginzburg S; Guzzo TJ; Lanchoney T; Marlowe B; Raman JD; Smaldone M; Tomaszewski JJ; Trabulsi EJ; Uzzo RG; Reese AC
    J Urol; 2019 May; 201(5):929-936. PubMed ID: 30720692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
    Luckenbaugh AN; Auffenberg GB; Hawken SR; Dhir A; Linsell S; Kaul S; Miller DC;
    J Urol; 2017 Mar; 197(3 Pt 1):621-626. PubMed ID: 27663459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
    Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
    Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of confirmatory prostate biopsy in active surveillance with national guidelines: An analysis from the multi-institutional PURC cohort.
    Talwar R; Friel B; Mittal S; Xia L; Fonshell C; Danella J; Jacobs B; Lanchoney T; Raman J; Tomaszewski J; Trabulsi E; Reese A; Singer EA; Ginzburg S; Smaldone M; Uzzo R; Mucksavage P; Guzzo TJ; Lee DJ
    Urol Oncol; 2020 Nov; 38(11):846.e17-846.e22. PubMed ID: 32739228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriateness Criteria for Active Surveillance of Prostate Cancer.
    Cher ML; Dhir A; Auffenberg GB; Linsell S; Gao Y; Rosenberg B; Jafri SM; Klotz L; Miller DC; Ghani KR; Bernstein SJ; Montie JE; Lane BR;
    J Urol; 2017 Jan; 197(1):67-74. PubMed ID: 27422298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Active Surveillance after Initial Surveillance Prostate Biopsy.
    Kovac E; Lieser G; Elshafei A; Jones JS; Klein EA; Stephenson AJ
    J Urol; 2017 Jan; 197(1):84-89. PubMed ID: 27449260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
    Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
    Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the United Kingdom.
    Philippou Y; Raja H; Gnanapragasam VJ
    BMC Urol; 2015 Jun; 15():52. PubMed ID: 26070313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
    Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
    J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
    Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
    J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer.
    Ginsburg KB; Arcot R; Qi J; Linsell SM; Kaye DR; George AK; Cher ML;
    J Urol; 2019 May; 201(5):923-928. PubMed ID: 30694939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.
    Mahal AR; Butler S; Franco I; Muralidhar V; Larios D; Pike LRG; Zhao SG; Sanford NN; Dess RT; Feng FY; D'Amico AV; Spratt DE; Yu JB; Nguyen PL; Rebbeck TR; Mahal BA
    Cancer; 2019 Oct; 125(19):3338-3346. PubMed ID: 31251398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.
    Radhakrishnan A; Wallner LP; Skolarus TA; George AK; Rosenberg BH; Abrahamse P; Hawley ST
    J Urol; 2022 Sep; 208(3):600-608. PubMed ID: 35522191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Pathological Outcomes for Men with Low Risk Prostate Cancer from Diverse Practice Settings: Similar Results from Immediate Prostatectomy or Initial Surveillance with Delayed Prostatectomy.
    Auffenberg GB; Linsell S; Dhir A; Myers SN; Rosenberg B; Miller DC;
    J Urol; 2016 Nov; 196(5):1415-1421. PubMed ID: 27256204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
    J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
    Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
    J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance for prostate cancer: an underutilized opportunity for reducing harm.
    Carter HB
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):175-83. PubMed ID: 23271770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.